Johnson & Johnson
JNJ: XNYS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| %%> | LOCK|W#$ | LOCK|Yb%$F$< |
Johnson & Johnson: Intra-Cellular Boosts Growth in Neuroscience and Fits With Industry Trend
On Jan.13, Johnson & Johnson announced that it plans to acquire Intra-Cellular and its schizophrenia and depression drug Caplyta for $14.6 billion.
